Intra Vaginal Drug for Treatment of Polycystic Ovary Syndrome
DOI:
https://doi.org/10.61841/k0vc0m54Keywords:
Polycystic ovary syndrome (PCOS), Endocrinopathy, Metformin, Hirsutism, Insulin resistance, Clomiphene, hyperinsulinemia, In vitro fertilizationAbstract
Polycystic ovary syndrome is the ordinary also the most controversial endocrinological syndrome affecting 4-10 percent of women. The Polycystic ovary syndrome PCOS is an endocrinopathy characterize by the augmented insulin resistance. The vaginal mucosal cavity is a viable, secure, highly attractive drug delivery site and highly versatile in drug absorption, metabolism, and removal. Logically, metformin was introduced to determine the extent to which hyperinsulinemia affects the condition's pathogenesis. Additionaly, sustained contact with the vaginal mucosa of a delivery system can be accomplished more effectively than at the other absorption sites such as intestinal mucosa or rectum. For the women with PCOS who are not overweight the Metformin is an active ovulation induction agent and provides few benefits for an ovulatory infertility such as clomiphene over other firstline therapies. Metformin should be given to women with the PCOS undergo in vitro fertilization to decrease their risk.of ovarian hyperstimulation syndrome. Limited evidence signifies that metformin may be a suitable alternative to oral contraceptive pill (OCP) in the treatment hyperandrogenic symptoms of PCOS, including hirsutism and acne.
Downloads
References
[1] H. Lashen, “Review: Role of metformin in the management of polycystic ovary syndrome,” Therapeutic
Advances in Endocrinology and Metabolism, vol. 1, no. 3. pp. 117–128, 2010.
[2] “ResearchGate.” [Online]. Available:
https://www.researchgate.net/publication/38112987_Mucoadhesive_Vaginal_Drug_Delivery_Systems.
[Accessed: 22-Nov-2019].
[3] R. Mathur, C. J. Alexander, J. Yano, B. Trivax, and R. Azziz, “Use of metformin in polycystic ovary
syndrome,” 2008.
[4] M. Phil, “A Dissertation On STUDY TO EVALUATE THE CHANGES IN POLYCYSTIC OVARIAN
MORPHOLOGY AFTER NATUROPATHIC AND YOGIC INTERVENTIONS POST GRADUATE
DEPARTMENT OF NATUROPATHY GOVERNMENT YOGA AND NATUROPATHY MEDICAL
COLLEGE AND HOSPITAL, CHENNAI-600 106,” 2018.
[5] J. Zhang, Q. Si, J. L.-P. journal of medical sciences, and undefined 2017, “Therapeutic effects of
metformin and clomiphene in combination with lifestyle intervention on infertility in women with obese
polycystic ovary syndrome,” ncbi.nlm.nih.gov.
[6] E. Graham, J. S.-J. of theoretical biology, and undefined 2017, “A model of ovulatory regulation
examining the effects of insulin-mediated testosterone production on ovulatory function,” Elsevier.
[7] E. Diamanti-Kandarakis, A. P.-T. in molecular medicine, and undefined 2006, “Molecular mechanisms of
insulin resistance in polycystic ovary syndrome,” Elsevier.
[8] N. Sekar, J. V.- Endocrinology, and undefined 2001, “Concerted transcriptional activation of the low
density lipoprotein receptor gene by insulin and luteinizing hormone in cultured porcine granulosa-luteal
cells: possible,” academic.oup.com
[9] I. Alanbay, C. M. Ercan, M. Sakinci, H. Coksuer, M. Ozturk, and S. Tapan, “A macrophage activation
marker chitotriosidase in women with PCOS: Does low-grade chronic inflammation in PCOS relate to
PCOS itself or obesity?,” Arch. Gynecol. Obstet., vol. 286, no. 4, pp. 1065–1071, Oct. 2012.
[10] A. G. Kebapcilar et al., “Cornea in PCOS patients as a possible target of IGF-1 action and insulin
resistance,” Arch. Gynecol. Obstet., vol. 290, no. 6, pp. 1255–1263, 2014.
[11] K. Osz, M. Ross, and J. Petrik, “The thrombospondin-1 receptor CD36 is an important mediator of ovarian
angiogenesis and folliculogenesis,” Reprod. Biol. Endocrinol., vol. 12, no. 1, Mar. 2014.
[12] O. Hakimi and L. C. Cameron, “Effect of Exercise on Ovulation: A Systematic Review,” Sports Medicine,
vol. 47, no. 8. Springer International Publishing, pp. 1555–1567, 01-Aug-2017
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
